Vaccine Company, Inc.

Vaccine Company, Inc. develops In Vivo Nanoparticle (IVN) technologies for antigen display to elicit durable immune responses, avoiding traditional VLP manufacturing. Its lead preclinical program targets Epstein-Barr Virus (EBV) with a five-antigen Phase 1-ready candidate, aiming to prevent acute infection and long-term risks like multiple sclerosis and malignancies.